Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Modifications of PUVA

K Momtaz-T1, T B Fitzpatrick

  • 1Department of Dermatology, Harvard Medical School, Massachusetts General Hospital, Boston 02114, USA.

Dermatologic Clinics
|October 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Early death from clinical stage I melanoma.

The Journal of investigative dermatology·2010
Same author

Factors associated with death from melanoma from 2 to 5 years following diagnosis in clinical stage I patients.

The Journal of investigative dermatology·2010
Same author

The "missing link" in the chain of discovery of early melanoma of the skin.

Proceedings (Baylor University. Medical Center)·2005
Same author

Structure and characterization of the glycan moiety of L-amino-acid oxidase from the Malayan pit viper Calloselasma rhodostoma.

European journal of biochemistry·2001
Same author

Chorismate synthase from the hyperthermophile Thermotoga maritima combines thermostability and increased rigidity with catalytic and spectral properties similar to mesophilic counterparts.

The Journal of biological chemistry·2001
Same author

A comparison of some of the methods available for analysing the substrate dependence of the exchange of the alpha-protons of amino acids catalysed by pyridoxal-phosphate-dependent enzymes.

Biochemical Society transactions·2000
Same journal

The Evidence Is In: Devices and Biologics Reshaping Modern Dermatology.

Dermatologic clinics·2026
Same journal

Energy-Based Devices for Body Contouring.

Dermatologic clinics·2026
Same journal

Microfocused Ultrasound with Visualization for Skin Tightening: Clinical Applications, Safety, and Technical Considerations.

Dermatologic clinics·2026
Same journal

Devices in Onychomycosis: A Status Update.

Dermatologic clinics·2026
Same journal

Acne Laser Devices in Dermatology.

Dermatologic clinics·2026
Same journal

Fractional Laser Therapy for Androgenetic Alopecia: Mechanisms, Clinical Evidence, and Practical Implementation.

Dermatologic clinics·2026
See all related articles

Photochemotherapy for psoriasis aims to reduce treatments and doses while maintaining disease control. Modifications and combinations of PUVA therapy enhance efficacy and minimize side effects.

Area of Science:

  • Dermatology
  • Photomedicine

Background:

  • Psoriasis is a chronic skin condition requiring effective treatment.
  • Current photochemotherapy aims to minimize treatment burden and adverse effects.

Purpose of the Study:

  • To explore modifications and combinations of PUVA (psoralen plus ultraviolet A) therapy for psoriasis.
  • To enhance treatment efficacy and reduce short- and long-term adverse effects.
  • To lower overall treatment costs.

Main Methods:

  • Modifying PUVA with improved psoralen preparations and light sources.
  • Combining PUVA with other therapeutic agents and modalities.
  • Evaluating efficacy, safety, and cost-effectiveness.

Main Results:

Related Experiment Videos

  • Modified PUVA and combination therapies show potential for improved psoriasis control.
  • Strategies aim to reduce exposure frequency and cumulative dosage.
  • Adverse effects and treatment costs are key considerations.

    • Conclusions:

    • Optimizing photochemotherapy, including PUVA, is crucial for effective psoriasis management.
    • Combining PUVA with agents like corticosteroids, calcipotriene, or methotrexate may improve outcomes.
    • Further research into modified and combination therapies can enhance patient care and reduce treatment burden.